This study is in progress, not accepting new patients
A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UCSD UCSF
- Dates
- study startedcompletion around
- Principal Investigator
- by Alain Algazi (ucsf)
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at University of California Health
- Alain Algazi (ucsf)
Dr. Alain Algazi is a specialist in medical treatment – such as chemotherapy and immunotherapy – for patients with head and neck cancers, including head and neck squamous cell carcinoma, thyroid cancers and salivary gland cancers. He leads UCSF's program in medical therapy for head and neck cancers, and chairs the head and neck cancer research committee.
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- ISA Pharmaceuticals
- ID
- NCT03669718
- Phase
- Phase 2 research study
- Study Type
- Interventional
- Participants
- Expecting 194 study participants
- Last Updated